THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL No. 1240 Session of 1977

INTRODUCED BY MCLANE, KELLY, TRELLO, A. K. HUTCHINSON, RAVENSTAHL, MISCEVICH, GILLETTE, BROWN, JONES, HASAY, LEVI, FREIND AND F. TAYLOR, JUNE 6, 1977

REFERRED TO COMMITTEE ON HEALTH AND WELFARE, JUNE 6, 1977

AN ACT

1 2 3	Permitting the use of amygdalin (laetrile) by persons who receive a prescription for same; authorizing physicians to prescribe amygdalin.
4	The General Assembly of the Commonwealth of Pennsylvania
5	hereby enacts as follows:
6	Section 1. A hospital or other health care facility may not
7	interfere with the physician-patient relationship by restricting
8	or forbidding the use of amygdalin (laetrile) as an adjunct to
9	recognized, customary or accepted modes of therapy in the
10	treatment of any malignancy, disease, illness or physical
11	condition when it is prescribed or administered by any person
12	licensed to practice medicine in this Commonwealth and the
13	patient has signed the "written informed request" therefor as
14	set forth in section 5.
15	Section 2. A person licensed to practice medicine may not be

15 Section 2. A person ficensed to practice medicine may not be 16 subjected to disciplinary action by any licensing board for 17 prescribing or administering amygdalin (laetrile) to a patient 18 under his care as an adjunct to recognized, customary or accepted modes of therapy in the treatment of any malignancy,
 disease, illness or physical condition, if and when the patient
 has signed the "written informed request" therefor as set forth
 in section 5.

5 Section 3. A person licensed to practice medicine may 6 prescribe or administer amygdalin (laetrile) in lieu of or in 7 addition to customary or accepted modes of therapy in the 8 treatment of any malignancy, disease, illness or physical 9 condition of a patient who has signed the "written informed 10 request" as set forth in section 5.

11 Section 4. Nothing in this act shall be construed as constituting an endorsement of amygdalin (laetrile) for the 12 13 treatment of any malignancy, disease, illness or physical condition, and nothing in this act shall be construed as 14 15 preventing a physician from prescribing amygdalin (laetrile) as 16 a dietary supplement to a patient not suffering from any known 17 malignancy, disease, illness or physical condition upon 18 execution of said "written informed request" therefor. 19 Section 5. The "written informed request" referred to in 20 this act shall be on a form prepared by, and obtained from, the State Board of Medical Education and Licensure and shall be in 21 22 substance as follows: 23 WRITTEN INFORMED REQUEST 24 FOR PRESCRIPTION OF AMYGDALIN (LAETRILE) FOR MEDICAL TREATMENT 25 26 Patient's name:..... 27 Address..... 28 Age.....Sex.....Sex..... 29 Name and address of prescribing physician: 30

19770H1240B1462

- 2 -

Malignancy, disease, illness or physical condition diagnosed 1 for medical treatment by amygdalin (laetrile) or its use as a 2 dietary supplement: 3 4 5 My physician has explained to me: 6 7 That the manufacture and distribution of amygdalin (a) (laetrile) has been banned by the Federal Food and Drug 8 Administration. 9 10 (b) That neither the American Cancer Society, the 11 American Medical Association, nor the Pennsylvania Medical Society recommend use of amygdalin (laetrile) in the 12 13 treatment of any malignancy, disease, illness or physical condition. 14 15 (c) That there are alternative recognized treatments for 16 the malignancy, disease, illness or physical condition from which I suffer which he has offered to provide for me 17 18 including: (Here describe) 19 20 21 That notwithstanding the foregoing, I hereby request 22 prescription and use of amygdalin (laetrile) (a) in the medical treatment of the malignancy, disease, illness or physical 23 condition from which I suffer [], or (b) as a dietary 24 supplement [] (check (a) or (b)). 25 26 27 Patient or person signing for patient 28 ATTEST: 29 30 Prescribing physician

19770H1240B1462

- 3 -

A copy of such "written informed request" shall be forwarded
 forthwith after execution thereof to the State Board of Medical
 Registration and Examination for appropriate filing.

Section 6. (a) Nothing in this act requires any physician,
any pharmacist, any pharmacy, any manufacturer or distributor to
manufacture, sell or distribute amygdalin (laetrile), and
nothing requires any physician to prescribe amygdalin (laetrile)
for any patient.

9 (b) If the Federal Government indicates that it will 10 withdraw all Federal funds from a health care facility for 11 allowing amygdalin (laetrile) to be used within the facility, and if providing or allowing its use within the facility would 12 13 jeopardize the receipt of Federal funds for reimbursement for 14 Medicare or Medicaid for all persons within the facility, or any 15 construction funds provided by the Federal Government under the 16 Hill-Burton Hospital Construction Program or under Title XVI of 17 the Public Health Services Act, the hospital or other health 18 care facility may, notwithstanding the provisions of section 1, 19 prohibit the use of amygdalin (laetrile) within its facility. 20 Section 7. This act shall take effect immediately.

E24L32JLW/19770H1240B1462 - 4 -